Freitag, 29. März 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE

Circulating Tumor Cells (CTC) in Cancer

Rekrutierend

NCT-Nummer:
NCT04520672

Studienbeginn:
Oktober 2020

Letztes Update:
20.02.2024

Wirkstoff:
-

Indikation (Clinical Trials):
Neoplastic Cells, Circulating

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
-

Sponsor:
University Hospital, Basel, Switzerland

Collaborator:
-

Studienleiter

Marcus Vetter, PD Dr. med.
Principal Investigator
Kantonsspital Baselland, Liestal

Kontakt

Studienlocations
(2 von 2)

Department Oncology, Haematology & Immuntherapy, Kantonsspital Baselland
4410 Liestal
SwitzerlandRekrutierend» Google-Maps
Ansprechpartner:
Marcus Vetter, PD Dr. med.
Phone: +41 61 925 27 15
E-Mail: marcus.vetter@ksbl.ch
» Ansprechpartner anzeigen

Studien-Informationen

Brief Summary:

This observational study with circulating tumor cells (CTC) count, isolation and analysis at

several time points during disease progression is to investigate the role and biology of CTCs

and clusters of CTCs in different cancer types. It also evaluates the role of CTCs as

biomarkers, and aims at the identification of key signaling networks that are active in CTCs.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Adult cancer patients

- All patients with histology-based proved diagnosis of cancer, all stages and subtypes

can be included. Precancerous lesions cannot be included.

- All patients with the diagnosis of a solid tumor including adenocarcinoma, squamous

cell carcinoma, neuroendocrine carcinoma, sarcoma

- Written pathology report must be available.

- Written informed consent.

Exclusion Criteria:

- No written informed consent.

- No proved diagnosis of malignancy by pathology report.

- Patients with the diagnosis of blood cancer

Studien-Rationale

Primary outcome:

1. Overall survival (OS) in heterogeneous cancer population (Time Frame - Screening (Visit 1) until the date of death (assessed up to 240 months)):
overall survival (OS) in heterogeneous cancer population

2. Change in total number of isolated CTCs (Time Frame - Through study completion, an average of 20 years):
Change in total number of isolated CTCs

Secondary outcome:

1. Progression free survival (PFS) (Time Frame - Through study completion, an average of 20 years):
progression free survival (PFS) in the different cancer cohorts with different treatment regimes

Geprüfte Regime

  • Blood samples:
    Blood samples (3 ethylenediaminetetraacetic acid (EDTA) tubes with a volume of 7.5 ml blood each) will be processed for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.
  • Samples from tumor draining vessels:
    In case of tumor resection, 3 EDTA tubes (5 ml) will be withdrawn from the tumor draining vessels for CTC isolation and characterization, ranging from molecular analysis to culture and drug screen.

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"Circulating Tumor Cells (CTC) in Cancer"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.